14.9
C
London
Wednesday, September 11, 2024
Company
Each template in our ever growing studio library can be added and moved around within any page effortlessly with one click.
Latest
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies
HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company...
Kincora Investor Presentation
Kincora Investor Presentation
Melbourne, Australia--(ACN Newswire - September 10, 2024)...
Hong Kong – HKMC’s second infrastructure loan-backed securities issuance
HKMC's second infrastructure loan-backed securities issuance
************************************************************
The following is issued...
Popular
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies
HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company...
Kincora Investor Presentation
Kincora Investor Presentation
Melbourne, Australia--(ACN Newswire - September 10, 2024)...
Hong Kong – HKMC’s second infrastructure loan-backed securities issuance
HKMC's second infrastructure loan-backed securities issuance
************************************************************
The following is issued...
© 2004-2024 Webnewswire, All Rights Reserved